Kawashima O, Yamauchi M, Maezawa Y, Toda G
First Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Alcohol Clin Exp Res. 1996 Feb;20(1 Suppl):36A-39A. doi: 10.1111/j.1530-0277.1996.tb01725.x.
Administration of cimetidine, an H2-receptor antagonist increases blood alcohol concentrations. This has been attributed to decreased gastric first-pass metabolism of ethanol caused by cimetidine's inhibitory effect on gastric alcohol dehydrogenase (sigma-ADH) activity. Molecular studies on sigma-ADH showed that a point mutation might occur at position 287 (G --> T) of the sigma-ADH gene in Japanese deficient type of sigma-ADH activity. To clarify the relationship between first-pass metabolism of ethanol and polymorphism of sigma-ADH, we analyzed the nucleotide sequence at positions 287 and 294 of sigma-ADH in 11 individuals who were administered ethanol orally before and after treatment with cimetidine. Higher blood ethanol levels after cimetidine administration were found in 4 of 11 cases (group A), whereas high blood ethanol levels were observed in 7 of 11 cases (B group), irrespective of cimetidine administration. Genetic polymorphisms at position 287 and 294 were not observed in all subjects. Even in 59 Japanese men with various alcoholic liver diseases, no polymorphisms at position 287 were observed by restriction-length polymorphisms with Avail digestion after polymerase chain reaction.
H2受体拮抗剂西咪替丁的给药会增加血液中的酒精浓度。这归因于西咪替丁对胃酒精脱氢酶(sigma-ADH)活性的抑制作用导致乙醇的胃首过代谢降低。对sigma-ADH的分子研究表明,在日本sigma-ADH活性缺乏型中,sigma-ADH基因的第287位(G→T)可能发生点突变。为了阐明乙醇的首过代谢与sigma-ADH多态性之间的关系,我们分析了11名在服用西咪替丁前后口服乙醇的个体中sigma-ADH第287位和第294位的核苷酸序列。11例中有4例(A组)在服用西咪替丁后血乙醇水平升高,而11例中有7例(B组)无论是否服用西咪替丁均观察到高血乙醇水平升高现象。在所有受试者中均未观察到第287位和第294位的基因多态性。即使在59名患有各种酒精性肝病的日本男性中,通过聚合酶链反应后用Avail消化进行限制性片段长度多态性分析,也未观察到第287位的多态性。